12830 El Camino Real, Suite 400
Tel: (858) 558-2871
495 articles with Acadia Pharmaceuticals
ACADIA Pharmaceuticals Inc. announced that it will present at the following two investor conferences
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Thursday, May 7, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations.
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder.
ACADIA Pharmaceuticals Inc. announced financial results for the fourth quarter and full year ended December 31, 2019.
ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2, 2020, at 2:10 p.m. Eastern Time.
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
Feb. 12, 2020 14:00 UTC ACADIA to Host Conference Call and Webcast on Wednesday, February 26, 2020, at 5:00 p.m. Eastern Time SAN DIEGO--( BUSINESS WIRE )-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on February 26, 2020, at 5:00 p.m. East
ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020, at 10:00 a.m. Pacific Time, followed by a question and answer breakout session.
ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Stephanie Fagan has been appointed to the newly created position of Senior Vice President, Corporate Affairs and Chief Communications Officer
12/9/2019It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
The company presented full trial data at the 12th Clinical Trials on Alzheimer’s Disease meeting in San Diego on Wednesday.
ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Pimavanserin met the primary endpoint in the study, significantly reducing the risk of relapse of psychosis by 2.8 fold (Hazard Ratio (HR)=0.353, one-sided p=0.0023)
These are the top biotech companies headquartered in Biotech Beach based on 2018 revenue. Here’s the brief information including the revenue of each company.
Researchers from around the world are coming to present scientific research and clinical trial data for the disease.
12/2/2019Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.
The trial studied the efficacy and safety of adjunctive pimavanserin dosages in patients with predominantly negative symptoms of schizophrenia who had adequate control of positive symptoms with their current antipsychotic treatment.
ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced positive top-line results from its ADVANCE study, a 26-week, randomized, double-blind, placebo-controlled study in 403 patients. ADVANCE evaluated the efficacy and safety of adjunctive pimavanserin treatment in patients with predominantly negative symptoms of schizophrenia who have achieved adequate control of positive symptoms with their existing antipsychotic treatment.
Acadia Professional Taps Judge Paul W. Armstrong J.S.C. (Ret.) to Chair New Advisory Board, Adds Lili Brillstein, Bill Burns, and Brian Kern
Newly appointed board members include: The Honorable Paul W. Armstrong, J.S.C. (Ret.), M.A., J.D., LLM, as Chairman, and Lili Brillstein, MPH, Bill Burns, ACAS, MAAA, and Brian S. Kern, Esq. as members.
ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019
The live webcast will be available on ACADIA’s website, www.acadia-pharm.com, under the investors section and will be archived there through January 4, 2020.
ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
Dr. Subbiah will report to Serge Stankovic, M.D., M.S.P.H., ACADIA’s President and be responsible for corporate medical affairs including medical strategy, scientific communications, and medical science liaison activities.
ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, announced that it has initiated the Phase 3 LAVENDER placebo-controlled study to evaluate the efficacy and safety of trofinetide for girls and young women with Rett syndrome.